Search

Your search keyword '"Halfvarson, Jonas"' showing total 92 results

Search Constraints

Start Over You searched for: Author "Halfvarson, Jonas" Remove constraint Author: "Halfvarson, Jonas" Journal gastroenterology Remove constraint Journal: gastroenterology
92 results on '"Halfvarson, Jonas"'

Search Results

2. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis

3. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition

5. Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies

7. Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE

8. Sa1583: SERUM PROTEOMIC MARKERS THAT PREDICT FUTURE CROHN'S DISEASE DEVELOPMENT ARE ASSOCIATED WITH GUT BARRIER FUNCTION, SUBCLINICAL GUT INFLAMMATION AND IMMUNE RESPONSE TO BACTERIAL ANTIGENS

11. Challenges and Opportunities in IBD Clinical Trial Design

12. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

13. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

16. Su1759 IDENTIFICATION AND VALIDATION OF A LIPIDOMIC SIGNATURE AS A NOVEL DIAGNOSTIC BIOMARKER OF PEDIATRIC INFLAMMATORY BOWEL DISEASE

17. Su1757 A NOVEL DIAGNOSTIC SERUM PROTEIN SIGNATURE FOR PEDIATRIC INFLAMMATORY BOWEL DISEASE: A DISCOVERY AND VALIDATION STUDY IN TWO INDEPENDENT INCEPTION COHORTS

18. Su1758 A NOVEL SERUM PROTEIN SIGNATURE AS BIOMARKER FOR INFLAMMATORY BOWEL DISEASE: A DIAGNOSTIC PERFORMANCE AND PREDICTION MODELLING STUDY USING DATA FROM TWO INDEPENDENT INCEPTION COHORTS

23. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

24. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

25. 398 THE GEM PROJECT: IDENTIFICATION OF A SERUM PROTEOMIC SIGNATURE ASSOCIATED WITH RISK OF FUTURE CROHN'S DISEASE ONSET IN A COHORT OF HEALTHY AT-RISK INDIVIDUALS

26. Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY

27. Mo1886 REAL-WORLD EFFECTIVENESS OF VEDOLIZUMAB IN CROHN'S DISEASE: WEEK 52 RESULTS FROM THE SWEDISH MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL SVEAH CD STUDY

28. Mo1115 WHOLE-BLOOD EXPRESSION PROFILES IN INFLAMMATORY BOWEL DISEASE REVEAL TRANSCRIPTION FACTOR INVOLVEMENT

30. Mo1764 – Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease

31. Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm

33. Mo1894 - Clinical Effectiveness of Vedolizumab: Interim Analysis of the Swedish Observational Study on Vedolizumab Assessing Effectiveness and Healthcare Resource Utilization in Patients with Ulcerative Colitis (Sveah UC)

36. Mo1892 - Clinical Effectiveness of Vedolizumab: Interim Analysis of the Swedish Observational Study on Vedolizumab Assessing Effectiveness and Healthcare Resource Utilization in Patients with Crohn's Disease (Sveah CD)

37. Epigenetic Alterations at Diagnosis Predict Susceptibility, Prognosis and Treatment Escalation in Inflammatory Bowel Disease and IBD Character

38. Su1784 PEA Immunoassay Technology Identifies Novel Serum Biomarkers That Can Diagnose and Classify Inflammatory Bowel Diseases: IBD Character Consortium

39. Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel

40. Tu1368 Vedolizumab in Inflammatory Bowel Disease, the First Experience From the Swedish IBD Registry (SWIBREG)

41. Mo1802 Intestinal Dysbiosis in Collagenous Colitis

42. Su1201 Proximity Extension Assay Technology Identifies Novel Serum Biomarkers for Predicting Inflammatory Bowel Disease: IBD Character Consortium

43. Su1316 Unchanged Surgery and Hospitalization Rates in an East-West European Inception Cohort Despite Differences in Use of Biologicals - 3-Year Follow-Up of the ECCO-EpiCom Cohort

44. Su1945 - Proximity Extension Assay based Proteins Show Immune Cell Specificity and can Diagnose and Predict Outcomes in Inflammatory Bowel Diseases: IBD Character Study

45. Su1827 - Epigenetic Alterations at Diagnosis Predict Susceptibility, Prognosis and Treatment Escalation in Inflammatory Bowel Disease and IBD Character

46. Sa1114 The Cost of Medical Management, Surgery and Clinical Investigations in a European Population-Based Inception Cohort From the Biological Era – An ECCO-Epicom Study

47. 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants

48. 1003 Association of Protective IL13 Polymorphism With Irritable Bowel Syndrome

49. Tu1933 Influence of Genetics in the Expression of Serological Markers in Twins With IBD

50. Mo1004 Is There an East-West Gradient in the Incidence of IBD in Europe? and Further Far East in China? First Results From the Epicom Study

Catalog

Books, media, physical & digital resources